Current Value
$2.381 Year Return
Current Value
$2.381 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IONQ | <0.01% | $10.39B | +399.37% | 0.00% |
NGG | -0.01% | $70.06B | +25.61% | 4.24% |
NNVC | 0.02% | $24.43M | -37.96% | 0.00% |
COST | -0.03% | $442.05B | +17.57% | 0.48% |
DAVE | -0.04% | $3.09B | +509.34% | 0.00% |
JBGS | 0.04% | $1.31B | +23.28% | 3.88% |
RCEL | 0.05% | $150.55M | -31.53% | 0.00% |
TW | -0.06% | $29.19B | +32.10% | 0.32% |
IAS | 0.06% | $1.36B | -11.37% | 0.00% |
TRMD | 0.06% | $1.70B | -51.08% | 22.20% |
KRP | 0.07% | $1.30B | -17.70% | 12.11% |
AON | 0.08% | $75.47B | +18.48% | 0.78% |
TRP | -0.08% | $51.54B | +39.35% | 5.17% |
CARV | 0.08% | $8.38M | -11.35% | 0.00% |
UNFI | -0.09% | $1.34B | +60.25% | 0.00% |
FE | 0.09% | $23.21B | +4.04% | 4.23% |
QNRX | -0.09% | $4.99M | -65.84% | 0.00% |
AVAL | -0.13% | $1.06B | +25.89% | 4.21% |
TPL | 0.13% | $25.29B | +43.48% | 0.54% |
INVH | 0.14% | $20.42B | -4.94% | 3.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -21.25% | $153.01M | 0.85% |
GBIL | -21.20% | $6.05B | 0.12% |
TAIL | -17.53% | $107.77M | 0.59% |
BTAL | -14.96% | $298.87M | 1.43% |
USFR | -12.48% | $18.83B | 0.15% |
FXY | -10.90% | $857.17M | 0.4% |
TPMN | -10.82% | $30.67M | 0.65% |
SGOV | -10.68% | $48.57B | 0.09% |
TBLL | -10.27% | $2.26B | 0.08% |
XONE | -9.07% | $634.70M | 0.03% |
IBD | -8.98% | $381.73M | 0.43% |
XBIL | -8.86% | $782.51M | 0.15% |
TFLO | -7.95% | $6.97B | 0.15% |
UNG | -7.21% | $372.51M | 1.06% |
IBTF | -7.03% | $2.07B | 0.07% |
ICSH | -6.67% | $6.15B | 0.08% |
BILZ | -6.39% | $839.99M | 0.14% |
BIL | -6.39% | $44.07B | 0.1356% |
XHLF | -5.48% | $1.64B | 0.03% |
CANE | -5.41% | $10.08M | 0.29% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BULL | 41.78% | $5.04B | -1.71% | 0.00% |
FERG | 32.03% | $42.08B | +2.21% | 1.15% |
BW | 29.81% | $120.05M | -13.48% | 0.00% |
TPST | 29.66% | $27.51M | -81.40% | 0.00% |
GEF | 29.11% | $3.75B | +4.02% | 3.34% |
CTRN | 28.95% | $275.90M | +51.16% | 0.00% |
MP | 27.52% | $4.19B | +75.14% | 0.00% |
ANGO | 27.41% | $442.62M | +77.52% | 0.00% |
AQN | 26.80% | $4.65B | -0.17% | 5.15% |
MSA | 25.75% | $6.49B | -6.65% | 1.25% |
STX | 25.63% | $26.84B | +22.98% | 2.25% |
AYI | 25.42% | $8.48B | +6.78% | 0.24% |
WDC | 25.09% | $19.42B | -6.97% | 0.18% |
HXL | 24.98% | $4.53B | -12.81% | 1.15% |
SYNA | 24.40% | $2.49B | -32.28% | 0.00% |
CMBT | 24.15% | $1.86B | -39.36% | 2.82% |
INVA | 23.57% | $1.34B | +34.40% | 0.00% |
CATX | 23.54% | $243.47M | -75.34% | 0.00% |
LFUS | 23.39% | $5.55B | -13.78% | 1.23% |
STHO | 23.36% | $99.63M | -42.19% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -13.70% | $97.17B | +37.77% | 3.95% |
STTK | -13.01% | $51.74M | -83.73% | 0.00% |
CVM | -13.01% | $12.73M | -93.78% | 0.00% |
LRN | -11.58% | $6.19B | +108.09% | 0.00% |
KVUE | -10.87% | $41.95B | +21.66% | 3.73% |
KR | -10.26% | $43.03B | +28.80% | 1.97% |
K | -9.91% | $28.31B | +38.89% | 2.82% |
MKTX | -9.30% | $8.44B | +11.89% | 1.32% |
IRWD | -8.81% | $116.79M | -88.69% | 0.00% |
MOH | -8.78% | $15.97B | -3.35% | 0.00% |
CABO | -8.64% | $756.82M | -62.63% | 6.62% |
FLYW | -7.96% | $1.32B | -35.62% | 0.00% |
PSO | -7.95% | $10.07B | +21.18% | 2.15% |
INSW | -7.90% | $1.85B | -30.43% | 1.26% |
MO | -7.46% | $100.92B | +30.61% | 6.82% |
NTZ | -7.46% | $43.62M | -22.35% | 0.00% |
IMNN | -7.45% | $29.12M | +36.07% | 0.00% |
DFDV | -7.35% | $380.05M | +2,345.35% | 0.00% |
EIX | -6.83% | $19.09B | -32.55% | 6.47% |
STNG | -6.67% | $2.10B | -48.53% | 4.80% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EMGF | 26.08% | $891.00M | 0.26% |
EWH | 26.03% | $638.57M | 0.5% |
REMX | 26.02% | $287.85M | 0.58% |
EYLD | 25.90% | $512.69M | 0.63% |
FLRT | 25.69% | $492.91M | 0.6% |
IWMY | 25.28% | $109.69M | 1.02% |
EMXF | 24.76% | $100.39M | 0.17% |
ESGE | 24.60% | $4.90B | 0.26% |
JPEM | 24.23% | $338.64M | 0.44% |
FNDE | 24.20% | $6.84B | 0.39% |
AVEM | 24.16% | $10.24B | 0.33% |
PFXF | 23.97% | $1.79B | 0.4% |
GEM | 23.90% | $990.00M | 0.45% |
PFLD | 23.53% | $493.44M | 0.45% |
PXH | 23.50% | $1.47B | 0.47% |
EEM | 23.44% | $17.82B | 0.72% |
AIA | 23.34% | $713.88M | 0.5% |
AAXJ | 23.04% | $2.62B | 0.72% |
DEHP | 22.99% | $250.18M | 0.41% |
DFEM | 22.97% | $5.34B | 0.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTH | 0.04% | $1.57B | 0.07% |
ZROZ | -0.11% | $1.49B | 0.15% |
SCHQ | -0.18% | $769.91M | 0.03% |
VGSH | 0.19% | $22.40B | 0.03% |
KCCA | 0.26% | $93.93M | 0.87% |
VTIP | -0.30% | $15.09B | 0.03% |
IGOV | 0.37% | $1.12B | 0.35% |
NUBD | 0.48% | $390.81M | 0.16% |
SMIN | 0.51% | $915.41M | 0.75% |
BSV | 0.51% | $38.07B | 0.03% |
EUSB | 0.55% | $718.77M | 0.12% |
UTWO | -0.60% | $374.41M | 0.15% |
TLT | 0.66% | $48.66B | 0.15% |
GOVZ | 0.70% | $260.33M | 0.1% |
SHY | -0.72% | $23.88B | 0.15% |
EDV | 0.74% | $3.33B | 0.05% |
IBTG | -0.76% | $1.94B | 0.07% |
BBAG | 0.83% | $1.29B | 0.03% |
CMBS | -0.92% | $438.36M | 0.25% |
KMLM | -0.95% | $192.65M | 0.9% |
Yahoo
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). T
Yahoo
Is it a good or bad thing when a stock experiences a golden cross technical event?
Yahoo
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo
ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Tuesday, June 17, 2025. The discussion will cover a general overview of the Claudin 18.2 landscape as a validated therapeutic target for gastric cancers.
Finnhub
Transforming Potential into Reality Mab Biopharma June 2025 ...
Yahoo
The U.S. stock market has recently faced turbulence, with major indices like the Dow Jones and Nasdaq experiencing declines amid renewed trade tensions and economic uncertainty. Despite these challenges, investors continue to explore diverse opportunities, including those presented by penny stocks. Although often associated with smaller or newer companies, penny stocks can offer significant potential for growth when backed by strong financials and solid business fundamentals.